ibreakstock/iStock via Getty Images
Biodexa (NASDAQ:BDRX) stock shot up 70% in morning trading Thursday after the company re-released positive data from a Phase 2 study for its drug eRapa in the treatment of Familial Adenomatous Polyposis, for FAP.
According to the company’s release Thursday, 12-month data from the Phase 2 study showed an overall non-progression rate of 75% and an overall median decrease in overall polyp burden of 17%. For patients in the cohort where they received eRapa daily every other week, the overall non-progression rate was 89% at 12 months, with a median reduction in polyp burden of 29%.
The company presented the data at the 2024 InSIGHT meeting in Barcelona, which was held June 19 to 22.
Biodexa issued a press release with the Phase 2 data on June 24.